Filing Flows › Cue Biopharma (CUE) › Q1 2026
Cue Biopharma (CUE) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 14, 2026
Cue Biopharma (CUE) reported revenue of $5.7M for the first quarter 2026 (Q1 2026), up 14-fold from a year earlier and -74% from the quarter before. Operating margin was -94.1%, net loss $5.2M (91.1% of revenue).
Cue Biopharma, Q1 2026: revenue $5.7M (14× year over year), operating margin -94.1%, net loss $5.2M, operating cash flow −$10.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.7M | -74% | 14× |
| Operating profit | −$5.4M | -371% | — |
| Net earnings | −$5.2M | -427% | — |
| Operating cash flow | −$10.9M | — | — |
What changed
Revenue was $5.7M in Q1 2026, up 1251% year over year and down 74% from the previous quarter.
Operating costs exceeded revenue by $5.4M, an operating margin of -94.1%. Total costs fell 13% while revenue rose 1251%. The quarter ended with a net loss of $5.2M, after a profit of $1.6M the previous quarter.
Operating cash flow was −$10.9M. Non-cash charges added back $566K of depreciation and amortization and $48K of share-based compensation. Working capital and other items used $6.4M. Capital expenditures of $121K exceeded it, leaving free cash flow of −$11.1M.
Questions
What was Cue Biopharma's revenue in the first quarter 2026?
Cue Biopharma (CUE) reported revenue of $5.7M for the first quarter 2026 (Q1 2026), up 14-fold from a year earlier and -74% from the quarter before.
Was Cue Biopharma profitable in the first quarter 2026?
Operating loss was $5.4M (-94.1% of revenue) and net loss $5.2M.
Source: Cue Biopharma 10-Q on SEC EDGAR.